Commentary
Video
Author(s):
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Five Under 5: Top Oncology Videos for the Week of 1/26
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
Nivolumab/Ipilimumab Approaches EU Approval in Unresectable or Advanced HCC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
T-DM1 Is Not Associated With Improved PFS vs Historical Controls in Pretreated HER2+ Biliary Tract Cancer
FDA Approval of Tislelizumab Plus Chemo Offers a New Option in Advanced Gastric/GEJ Adenocarcinoma
Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC
Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer
Dr Levy on the Development and Clinical Use of ADCs in NSCLC
Fox Chase Cancer Center’s Austin Williams Named 2025 Society of Surgical Oncology Presidential Scholar
CHMP Recommends Approval of Durvalumab for Limited-Stage Small Cell Lung Cancer
FDA Accepts BLA for Pertuzumab Biosimilar in HER2+ Breast Cancer
Encorafenib/Cetuximab Plus Chemo Improves Survival in BRAF V600E+ mCRC